What is the risk of recurrence of solitary plasmacytoma?

Updated: Mar 10, 2021
  • Author: Suzanne R Fanning, DO; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

SP is a highly radiosensitive tumor and most patients undergo radiation therapy as the first line of treatment, resulting in an excellent local control rate. [2] The risk of recurrence or progression to myeloma within 3 years is approximately 10% for patients with SP versus 20% to 60% for patients who have SP with minimal marrow involvement. [1]

For patient education information, see the Multiple Myeloma Health Center and What is solitary plasmacytoma?.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!